• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Residual Coronary Risk Factors Associated With Long-Term Clinical Outcomes in Patients With Coronary Artery Disease Treated With High- vs. Low-Dose Statin Therapy 　- REAL-CAD Substudy
CONCLUSIONS: Regarding nonlipid prognostic factors contributing to the incidence of cardiovascular events in statin-treated CAD patients, renal dysfunction was the most significant, followed by poor glucose control and high SBP.PMID:37482412 | DOI:10.1253/circj.CJ-23-0134
Source: Circulation Journal - July 23, 2023 Category: Cardiology Authors: Takumi Higuma Yoshihiro J Akashi Yoshihiro Fukumoto Hitoshi Obara Tatsuyuki Kakuma Yasuhide Asaumi Satoshi Yasuda Ichiro Sakuma Hiroyuki Daida Hiroaki Shimokawa Takeshi Kimura Satoshi Iimuro Ryozo Nagai Source Type: research

Low-Density Lipoprotein Cholesterol Levels on Statins and Cardiovascular Event Risk in Stable Coronary Artery Disease 　- An Observation From the REAL-CAD Study
CONCLUSIONS: A very low on-treatment LDL-C level (<70 mg/dL) was not associated with lower cardiovascular event risk compared with moderately low on-treatment LDL-C level (70-100 mg/dL) in patients receiving the same doses of statins.PMID:36104250 | DOI:10.1253/circj.CJ-22-0168
Source: Circulation Journal - September 14, 2022 Category: Cardiology Authors: Toshiaki Toyota Takeshi Morimoto Satoshi Iimuro Retsu Fujita Hiroshi Iwata Katsumi Miyauchi Teruo Inoue Yoshihisa Nakagawa Yosuke Nishihata Hiroyuki Daida Yukio Ozaki Satoru Suwa Ichiro Sakuma Yutaka Furukawa Hiroki Shiomi Hirotoshi Watanabe Kyohei Yamaji Source Type: research

Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease 　- Insights From the REAL-CAD Study
CONCLUSIONS: High-dose pitavastatin therapy compared with low-dose pitavastatin therapy was associated with a trend toward lowering the risk for cardiovascular events irrespective of the thrombotic risk in patients with CCS.PMID:35934778 | DOI:10.1253/circj.CJ-22-0315
Source: Circulation Journal - August 7, 2022 Category: Cardiology Authors: Masahiro Natsuaki Takeshi Morimoto Satoshi Iimuro Retsu Fujita Hiroshi Iwata Katsumi Miyauchi Teruo Inoue Yoshihisa Nakagawa Yosuke Nishihata Hiroyuki Daida Yukio Ozaki Satoru Suwa Ichiro Sakuma Yutaka Furukawa Hiroki Shiomi Hirotoshi Watanabe Kyohei Yama Source Type: research

Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects 　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial
CONCLUSIONS: Use of evolocumab robustly lowers LDL-C and is equally efficacious in lowering the risk of cardiovascular events and safe in Asians as it is in others.PMID:33980763 | DOI:10.1253/circj.CJ-20-1051
Source: Circulation Journal - May 13, 2021 Category: Cardiology Authors: Anthony C Keech Kazuma Oyama Peter S Sever Minao Tang Sabina A Murphy Atsushi Hirayama Chen Lu Leslie Tay Prakash C Deedwania Chung-Wah Siu Armando Lira Pineda Donghoon Choi Min-Ji Charng John Amerena Wan Azman Wan Ahmad Vijay K Chopra Terje R Pedersen Ro Source Type: research

Lipoprotein(a) and Cardiovascular Diseases 　- Revisited.
Lipoprotein(a) and Cardiovascular Diseases　- Revisited. Circ J. 2020 Apr 24;: Authors: Jang AY, Han SH, Sohn IS, Oh PC, Koh KK Abstract Two decades ago, it was recognized that lipoprotein(a) (Lp(a)) concentrations were elevated in patients with cardiovascular disease (CVD). However, the importance of Lp(a) was not strongly established due to a lack of both Lp(a)-lowering therapy and evidence that reducing Lp(a) levels improves CVD risk. Recent advances in clinical and genetic research have revealed the crucial role of Lp(a) in the pathogenesis of CVD. Mendelian randomization studies have shown that ...
Source: Circulation Journal - April 23, 2020 Category: Cardiology Authors: Jang AY, Han SH, Sohn IS, Oh PC, Koh KK Tags: Circ J Source Type: research

Fasting and Non-Fasting Triglycerides and Risk of Cardiovascular Events in Diabetic Patients Under Statin Therapy.
CONCLUSIONS: Non-fasting TG could be considered as a substitute for fasting TG as a risk stratification for future CV events among Japanese diabetic patients. PMID: 32023582 [PubMed - as supplied by publisher]
Source: Circulation Journal - February 5, 2020 Category: Cardiology Authors: Tada H, Nomura A, Yoshimura K, Itoh H, Komuro I, Yamagishi M, Takamura M, Kawashiri MA Tags: Circ J Source Type: research

Pages: 1  2